Author

Damon R. Demady

Observed names: D. Demady, Damon Demady

Observed institutions: National Institutes of Health, University of Michigan, National Heart, Lung, and Blood Institute, Michigan Medicine, Knopp Biosciences (United States), Mersana Therapeutics (United States)

ORCID: 0009-0002-9337-7634

Observed ORCID: 0009-0002-9337-7634

OpenAlex ID: A5074456493

Folding of the Glucocorticoid Receptor by the Heat Shock Protein (hsp) 90-based Chaperone Machinery

1997 · Kurt D. Dittmar, Damon R. Demady, et al. · Journal of Biological Chemistry · 265

Neuronal Nitric-oxide Synthase Is Regulated by the hsp90-based Chaperone System in Vivo

1999 · Andrew T. Bender, Adam M. Silverstein, et al. · Journal of Biological Chemistry · 159

Agmatine Enhances the NADPH Oxidase Activity of Neuronal NO Synthase and Leads to Oxidative Inactivation of the Enzyme

2001 · Damon R. Demady, Suree Jianmongkol, et al. · Molecular Pharmacology · 106

cDNA Cloning and Baculovirus Expression of the Human Liver Endoplasmic Reticulum P58: Characterization as a Protein Disulfide Isomerase Isoform, but Not as a Protease or a Carnitine Acyltransferase

1995 · Mohammed Bourdi, Damon Demady, et al. · Archives of Biochemistry and Biophysics · 96

Ubiquitination of Neuronal Nitric-oxide Synthase in Vitro and in Vivo

2000 · Andrew T. Bender, Damon R. Demady, et al. · Journal of Biological Chemistry · 90

Guanabenz-mediated Inactivation and Enhanced Proteolytic Degradation of Neuronal Nitric-oxide Synthase

2000 · Soichi Noguchi, Suree Jianmongkol, et al. · Journal of Biological Chemistry · 52

Effects of dexpramipexole on brain mitochondrial conductances and cellular bioenergetic efficiency

2012 · Kambiz N. Alavian, Steven I. Dworetzky, et al. · Brain Research · 51

The Dolaflexin-based Antibody–Drug Conjugate XMT-1536 Targets the Solid Tumor Lineage Antigen SLC34A2/NaPi2b

2021 · Natalya D. Bodyak, Rebecca Mosher, et al. · Molecular Cancer Therapeutics · 50

Aminoguanidine-mediated Inactivation and Alteration of Neuronal Nitric-oxide Synthase

2000 · Suree Jianmongkol, Jennifer L. Vuletich, et al. · Journal of Biological Chemistry · 34

Metabolism-based Inactivation of Neuronal Nitric-oxide Synthase by Components of Cigarette and Cigarette Smoke

2003 · Damon R. Demady, Ezra R. Lowe, et al. · Drug Metabolism and Disposition · 20

Alteration of the Heme Prosthetic Group of Neuronal Nitric-Oxide Synthase during Inactivation byNG-Amino-l-arginine in Vitro and in Vivo

2002 · Jennifer L. Vuletich, Ezra R. Lowe, et al. · Molecular Pharmacology · 16

Discovery of novel polyamide-pyrrolobenzodiazepine hybrids for antibody-drug conjugates

2022 · Joshua D. Thomas, Aleksandr V. Yurkovetskiy, et al. · Bioorganic & Medicinal Chemistry Letters · 5

Development of a Novel DNA Mono-alkylator Platform for Antibody–Drug Conjugates

2024 · Joshua D. Thomas, Aleksandr V. Yurkovetskiy, et al. · Molecular Cancer Therapeutics · 2

Practical Considerations in the Design of Preclinical Safety Assessments for Biopharmaceuticals

2007 · Damon R. Demady · Wiley eBooks · 1

Figure S5 from Development of a Novel DNA Mono-alkylator Platform for Antibody–Drug Conjugates

2026 · Joshua D. Thomas, Aleksandr V. Yurkovetskiy, et al.

Table S3 from Development of a Novel DNA Mono-alkylator Platform for Antibody–Drug Conjugates

2026 · Joshua D. Thomas, Aleksandr V. Yurkovetskiy, et al.

Figure S3 from Development of a Novel DNA Mono-alkylator Platform for Antibody–Drug Conjugates

2026 · Joshua D. Thomas, Aleksandr V. Yurkovetskiy, et al.

Figure S2 from Development of a Novel DNA Mono-alkylator Platform for Antibody–Drug Conjugates

2026 · Joshua D. Thomas, Aleksandr V. Yurkovetskiy, et al.

Figure S4 from Development of a Novel DNA Mono-alkylator Platform for Antibody–Drug Conjugates

2026 · Joshua D. Thomas, Aleksandr V. Yurkovetskiy, et al.

Figure S8 from Development of a Novel DNA Mono-alkylator Platform for Antibody–Drug Conjugates

2026 · Joshua D. Thomas, Aleksandr V. Yurkovetskiy, et al.

Figure S1 from Development of a Novel DNA Mono-alkylator Platform for Antibody–Drug Conjugates

2026 · Joshua D. Thomas, Aleksandr V. Yurkovetskiy, et al.

Table S6 from Development of a Novel DNA Mono-alkylator Platform for Antibody–Drug Conjugates

2026 · Joshua D. Thomas, Aleksandr V. Yurkovetskiy, et al.

Figure S6 from Development of a Novel DNA Mono-alkylator Platform for Antibody–Drug Conjugates

2026 · Joshua D. Thomas, Aleksandr V. Yurkovetskiy, et al.

Table S2 from Development of a Novel DNA Mono-alkylator Platform for Antibody–Drug Conjugates

2026 · Joshua D. Thomas, Aleksandr V. Yurkovetskiy, et al.

Table S1 from Development of a Novel DNA Mono-alkylator Platform for Antibody–Drug Conjugates

2026 · Joshua D. Thomas, Aleksandr V. Yurkovetskiy, et al.

Works count: 79

Citation count: 947

H-index: 11

I10-index: 11